 |
67 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
342 Trials |  |
12240 News |  |
| «12345678910111213...229230» |
- | dexamethasone / Generic mfg.
Journal: AEBP1 restores osteoblastic differentiation under dexamethasone treatment by activating PI3K/AKT signalling. (Pubmed Central) - Oct 3, 2024
Furthermore, LY294002 treatment decreased relative cell viability, Alizarin red staining, osteoblastic differentiation markers including OCN, OPN, RUNX2 and BMP, increased cell apoptosis rate and did not affect ALP staining in MC3T3-E1 cells under Dex treatment; meanwhile, LY294002 treatment weakened the effect of AEBP1 overexpression vectors on the above cell functions. AEBP1 restores osteoblastic differentiation under Dex treatment by activating the PI3K/AKT pathway.
- | Journal: Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. (Pubmed Central) - Oct 3, 2024
Meanwhile, the study elucidates that Sal sensitizes TNBC to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy, regulated by PI3K/AKT/mTOR signaling pathways. Our findings provide a theoretical basis for applying Sal to treat TNBC.
- || palazestrant (OP-1250) / Olema Pharma
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus (clinicaltrials.gov) - Oct 2, 2024
P1, N=155, Recruiting, Sponsor: Olema Pharmaceuticals, Inc.
Our findings provide a theoretical basis for applying Sal to treat TNBC. N=90 --> 155 | Trial completion date: Aug 2024 --> Jun 2026 | Trial primary completion date: Aug 2024 --> May 2026
- CRISPR-CAS9 KNOCKOUT SCREENING IDENTIFIES WRN AS AN ESSENTIAL GENE IN NEUROBLASTOMA () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1121;
N=90 --> 155 | Trial completion date: Aug 2024 --> Jun 2026 | Trial primary completion date: Aug 2024 --> May 2026 The study systematically analyzes the NB-dependent epigenetic regulatory genes and identifies WRN as a critical biomarker for NB progression, thereby offering a potential therapeutic target for intervention in NB treatment.
- Piqray (alpelisib) / Novartis
HRQoL, Symptom Severity, and Pain Among Patients Treated with Alpelisib for PROS (Poster Hall: Hyatt Regency Orlando, Plaza International Ballroom) - Oct 2, 2024 - Abstract #AAPNCE2024AAP_NCE_1185;
P, P=N/A
This real-world study provides important information from patients with PROS treated with alpelisib and their caregivers, including reported improvements in pain and functioning. These data complement those from EPIK-P1 (NCT04285723), wherein alpelisib demonstrated effectiveness and safety for the treatment of PROS, further supporting the clinical benefit of alpelisib for patients.
- ||| Arzerra (ofatumumab) / Novartis, Genmab, Copiktra (duvelisib) / Secura Bio, Yakult Honsha
P3 data, Journal: The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival. (Pubmed Central) - Oct 1, 2024
These data complement those from EPIK-P1 (NCT04285723), wherein alpelisib demonstrated effectiveness and safety for the treatment of PROS, further supporting the clinical benefit of alpelisib for patients. Not available.
- | LY294002 / Eli Lilly
Journal, Combination therapy, IO biomarker: Proapoptotic and antimigration properties of osthole in combination with LY294002 against human glioma cells. (Pubmed Central) - Oct 1, 2024
In addition, the combination of compounds induced apoptosis. New combination of compounds shows a high pro-apoptotic potential and also inhibits the migration of gliomas cells.
- | Journal: Retinoic Acid Improves Vascular Endothelial Dysfunction by Inhibiting PI3K/AKT/YAP-Mediated Ferroptosis in Diabetes Mellitus. (Pubmed Central) - Oct 1, 2024
New combination of compounds shows a high pro-apoptotic potential and also inhibits the migration of gliomas cells. ATRA could improve vascular endothelial dysfunction by inhibiting PI3K/AKT/YAP-mediated ferroptosis induced by HG, which provides a new idea for the treatment of vascular lesions in diabetes.
- | Journal: TYMS Knockdown Suppresses Cells Proliferation, Promotes Ferroptosis via Inhibits PI3K/Akt/mTOR Signaling Pathway Activation in Triple Negative Breast Cancer. (Pubmed Central) - Oct 1, 2024
Its underlying mechanism is related to the PI3K /Akt pathway. Our study provides a novel sight for the suppression effect of TYMS on TNBC.
- || PK/PD data, Journal: Comprehensive investigation of network pharmacology, computational modeling, and pharmacokinetic assessment to evaluate the efficacy of flavonoids in rheumatoid arthritis. (Pubmed Central) - Sep 30, 2024
Schaftoside and Vitexin showed no toxicity in computational approach and found suitable for further investigations. Overall, our study underscores the potential of flavonoids as therapeutic agents for RA and highlights the utility of integrative approaches combining network pharmacology, computational modeling, in silico methods, and pharmacokinetic assessment in drug discovery and development processes.
- ACTIVATED PI3K DELTA SYNDROME PRESENTING AS FAILURE TO THRIVE - A CASE REPORT (Monitor 11; Hall A) - Sep 29, 2024 - Abstract #ACAAI2024ACAAI_1155;
P3
Overall, our study underscores the potential of flavonoids as therapeutic agents for RA and highlights the utility of integrative approaches combining network pharmacology, computational modeling, in silico methods, and pharmacokinetic assessment in drug discovery and development processes. Growth Curves Concerning for Failure to Thrive Patient
- Joenja (leniolisib) / Pharming Group, Rituxan (rituximab) / Roche
ACTIVATED PHOSPHOINOSITIDE 3- KINASE D SYNDROME INITIALLY MISDIAGNOSED AS COMMON VARIABLE IMMUNODEFICIENCY (Monitor 12; Hall A) - Sep 29, 2024 - Abstract #ACAAI2024ACAAI_1040;
Rituximab was selected to treat his non-neoplastic proliferation and AIHA. Leniolisib, which is a PI3K-d inhibitor in clinical trials, was considered but deferred due to a lack of literature on its use in patients with AIHA.
- | cisplatin / Generic mfg.
Journal: Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT). (Pubmed Central) - Sep 29, 2024
Mechanistically, OXY suppressed the PI3K/AKT/mTOR signaling pathway by reducing phosphorylated AKT, while having no discernible effect on the MAPK pathway. These findings highlight OXY's potential to enhance ovarian cancer cell sensitivity to chemotherapy, suggesting its development as a pharmaceutical adjunct for clinical use in combination therapies.
- | LY294002 / Eli Lilly
Journal, IO biomarker: Role of PI3K/AKT signaling pathway involved in self-renewing and maintaining biological properties of chicken primordial germ cells. (Pubmed Central) - Sep 28, 2024
Our findings indicated that although supplementation with the PI3K/AKT activator IGF-1 failed to promote proliferation under the assessed culture conditions, the PI3K/AKT inhibitor LY294002 resulted in retarded cell proliferation and reduced expression of germ cell-related markers...These findings indicated that the PI3K/AKT pathway is required for cell renewal, apoptosis, and maintenance of the reproductive potential in chicken PGCs. This study aimed to provide a theoretical basis for the optimization and improvement of a culture system for chicken PGCs and provide insights into the self-renewal of vertebrate PGCs as well as potential evolutionary changes in this unique cell population.
- | miransertib (MK-7075) / Merck (MSD), LY294002 / Eli Lilly
Preclinical, Journal: Hesperetin alleviates aflatoxin B1 induced liver toxicity in mice: Modulating lipid peroxidation and ferritin autophagy. (Pubmed Central) - Sep 28, 2024
In summary, our results suggest that hesperetin not only regulates the antioxidant system but also inhibits AFB1-induced ferritin hyperautophagy, thereby reducing the accumulation of iron ions to mitigate lipid peroxidation. This work provides a fresh perspective on the mechanism behind hesperetin and AFB1-induced liver damage in mice.
- | LY294002 / Eli Lilly
Journal: LncRNA MALAT1 Expression Regulates Breast Cancer Progression via PI3K/AKT/mTOR Pathway Modulation. (Pubmed Central) - Sep 26, 2024
The study also investigated the cross-talk of lncRNA MALAT1 and PI3K pathway genes by inhibiting it with PI3K inhibitor (LY294002) in MDA-MB-231 cell line...Moreover, the study proposes a mechanism of action of MALAT1, demonstrating that its inhibition can reduce the expression of the PI3K/AKT/mTOR axis. These findings emphasize the potential significance of targeting MALAT1 as a therapeutic strategy for breast cancer, and further exploration of this interaction is warranted to gain deeper insight into the molecular mechanism of this lncRNA.
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: MEK inhibitors in oncology: a patent review and update (2016 - present). (Pubmed Central) - Sep 26, 2024
The MEK1/2 inhibitors in combination with other kinase (BRaf/KRas/PI3K) inhibitors showed significant anti-proliferative activity. Other combination of MEK inhibitor with PD-1, DYRK1, EGFR, BTK and/or VEGF inhibitors etc. showed promising results in many cancers including colorectal, pancreatic, gastrointestinal, solid tumor, breast cancer, melanoma and multiple myeloma etc. The dual or multi-targeted approaches of these combinations showed better and precise treatment of patients with resistant cancer.
- | Journal: Mechanisms of Yiai Fuzheng formula in the treatment of triple-negative breast cancer based on UPLC-Q-Orbitrap-HRMS, network pharmacology, and experimental validation. (Pubmed Central) - Sep 25, 2024
YAFZF therapy showed its potential for reducing proliferation, invasion, and migration abilities, increasing apoptosis of TNBC cells. Furthermore, YAFZF treated TNBC by inhibiting xenograft tumour distant metastases via the regulation of EMT by the PI3K/Akt/mTOR pathway, suggesting that it may be useful as an adjuvant treatment.
- LY294002 / Eli Lilly
Single Nuclei Multiome and Spatial Transcriptomic Analysis of Early, Untreated SSc Skin Identifies Signaling Interactions Between Macrophages and Fibroblasts (Hall E; In Person) - Sep 25, 2024 - Abstract #ACRConvergence2024ACR_Convergence_1099;
Increased PDGF and downstream PI3K activity is a hallmark of SSc skin fibrosis. PI3K inhibition reduces tissue thickness, providing a specific druggable target for disrupting the immune-fibrosis axis in SSc skin.
- | Preclinical, Journal, IO biomarker: Functionalized siRNA-chitosan nanoformulations promote triple-negative breast cancer cell death via blocking the miRNA-21/AKT/ERK signaling axis: in-silico and in vitro studies. (Pubmed Central) - Sep 24, 2024
The GE11-siRNA-CSNPs design, which specifically targets TNBC cells, offers a novel approach for the treatment of breast cancer with improved effectiveness. This study suggests that GE11-siRNA-CSNPs could be a promising candidate for further assessment as an additional strategy in the treatment of TNBC.
- | Journal: Hypoxia and loss of GCM1 expression prevents differentiation and contact inhibition in human trophoblast stem cells. (Pubmed Central) - Sep 24, 2024
Additionally, chromatin immunoprecipitation of GCM1 showed enrichment of GCM1-specific binding near key transcription factors upregulated upon differentiation including the contact inhibition factor CDKN1C. Loss of GCM1 resulted in downregulation of CDKN1C and corresponding loss of contact inhibition, implicating GCM1 in regulation of this critical process.
- | Preclinical, Journal, IO biomarker: Toll-like receptors (TLR2 and TLR4) antagonist mitigates the onset of cerebral small vessel disease through PI3K/Akt/GSK3? pathway in stroke-prone renovascular hypertensive rats. (Pubmed Central) - Sep 23, 2024
These results suggested that TLR4 and TLR2 antagonist achieved protective effect on the RHRSP through the PI3K/Akt/GSK3? pathway.
- | LY294002 / Eli Lilly
Preclinical, Journal: PAR-2 gene expression data and morphology data of rabbit Achilles tenocytes stimulated with PDGF-BB in vitro. (Pubmed Central) - Sep 23, 2024
Data on cell size, on F-actin immunohistochemical labeling intensity, ?-tubulin immunohistochemical labeling intensity and on cell aspect ratio (length of the cell divided by its width) are presented. Moreover, analogous to the first set of data, cytoskeletal rearrangement in the presence or absence of the inhibitors SB203580, LY-294002 and PD153035 in the presence or absence of PDGF-BB were assessed.
- | MK-2206 / Merck (MSD), LY294002 / Eli Lilly
Journal: ZDHHC20 Activates AKT Signaling Pathway to Promote Cell Proliferation in Hepatocellular Carcinoma. (Pubmed Central) - Sep 23, 2024
High expression of ZDHHC20 promotes the proliferation and tumor growth of HCC by activating the PI3K-AKT signaling pathway. The PI3K inhibitor LY294002 and the AKT inhibitor MK2206 inhibit the promotional effects of ZDHHC20 on the proliferation of HCC and the growth of tumors.
- | Journal: BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K/AKT pathway and represents a therapeutic target. (Pubmed Central) - Sep 22, 2024
The transcription factor FOXP1 was found to interact with BRD9 to regulate CST1 expression. Collectively, these results suggest that BRD9 may be a promising biomarker and therapeutic target for GBC.
- | buparlisib (AN2025) / Adlai Nortye
Journal: MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptation. (Pubmed Central) - Sep 22, 2024
Pharmacological blockade of autophagy (center) or lack of translocated MYC UR along with MYC CDS in BL (right) overcome resistance and induces cells death. Image created in BioRender.
- | Journal: Mechanisms insights into bisphenol S-induced oxidative stress, lipid metabolism disruption, and autophagy dysfunction in freshwater crayfish. (Pubmed Central) - Sep 21, 2024
In conclusion, BPS exposure induced oxidative stress, promoted lipid accumulation, and led to autophagy dysfunction in the hepatopancreas of freshwater crayfish. Collectively, our findings provide the first evidence that environmentally relevant levels of BPS exposure can induce hepatopancreatic lipid deposition through multiple pathways, raising concerns about the potential population-level harm of BPS and other bisphenol analogues.
- | Journal: Paraquat disrupts the blood-brain barrier by increasing IL-6 expression and oxidative stress through the activation of PI3K/AKT signaling pathway. (Pubmed Central) - Sep 20, 2024
Our study demonstrated that chronic PQ exposure could impair the BBB function and induce brain tissue damage. The overactivation of the PI3K/AKT pathway, consequent upregulation of IL-6 production, and increased oxidative stress appear to mediate the inflammatory damage resulting from PQ exposure.
- | Journal: JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway. (Pubmed Central) - Sep 20, 2024
Knockdown of JARID2 inhibited tumor growth and cell stemness in mice but was alleviated by concurrent overexpression of NFYA. NFYA promotes TNBC cell stemness by upregulating JARID2 expression and regulating the PI3K/AKT signaling pathway, suggesting JARID2 as a potential target for innovating drugs that target TNBC stem cells.
- | LY294002 / Eli Lilly
Journal: TXNIP Regulates NLRP3 Inflammasome-Induced Pyroptosis Related to Aging via cAMP/PKA and PI3K/Akt Signaling Pathways. (Pubmed Central) - Sep 20, 2024
Furthermore, we conducted experiments to modulate the improvement of TXNIP on NLRP3 inflammasome-induced pyroptosis, that is, the PI3K activator 740 Y-P and the PKA activator DC2797 inhibited the effect, while the PI3K inhibitor LY294002 and the PKA inhibitor H89 enhanced the effect. In conclusion, our study demonstrated that TXNIP regulates NLRP3 inflammasome-induced pyroptosis in HT-22 cells related to aging via the PI3K/Akt and cAMP/PKA pathways.
- | Journal: miR-30c-5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway. (Pubmed Central) - Sep 20, 2024
In conclusion, our study demonstrated that TXNIP regulates NLRP3 inflammasome-induced pyroptosis in HT-22 cells related to aging via the PI3K/Akt and cAMP/PKA pathways. In summary, we found that miR-30c-5p inhibited the proliferation, invasion and migration of ESCC by inhibiting PI3K/AKT signaling pathway for the first time, and this study is expected to provide a novel insight and potential therapeutic target for managing ESCC.
- | sorafenib / Generic mfg.
Journal: Resveratrol liposomes reverse sorafenib resistance in renal cell carcinoma models by modulating PI3K-AKT-mTOR and VHL-HIF signaling pathways. (Pubmed Central) - Sep 20, 2024
Further western blotting analysis suggested that RES-lips may enhance the resistance of RCC to sorafenib by inhibiting PI3K-AKT-mTOR and VHL-HIF signaling pathways, ultimately augmenting the tumor growth inhibition effect of the combination therapy. RES-lips may improve the sorafenib resistance in RCC, and the underlying mechanism may be related to the regulation of PI3K-AKT-mTOR and VHL-HIF signaling pathways.
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene, Brukinsa (zanubrutinib) / BeiGene, BGB-10188 / BeiGene
Trial completion, Combination therapy, Monotherapy: BGB-A317-3111-10188-101: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (clinicaltrials.gov) - Sep 19, 2024
P1/2, N=97, Completed, Sponsor: BeiGene
RES-lips may improve the sorafenib resistance in RCC, and the underlying mechanism may be related to the regulation of PI3K-AKT-mTOR and VHL-HIF signaling pathways. Active, not recruiting --> Completed
- | dichloroacetate topical / Generic mfg.
Preclinical, Journal: The role of PI3K-Akt-mTOR axis in Warburg effect and its modification by specific protein kinase inhibitors in human and rat inflammatory macrophages. (Pubmed Central) - Sep 17, 2024
The effect of kinase inhibitors on Warburg effect was variable in different cell types, whereas dichloroacetate caused a shift toward oxidative metabolism. Our findings suggest that these originally anti-cancer inhibitors may also be candidates for anti-inflammatory therapy.
- || Istodax (romidepsin) / Astellas, BMS, Copiktra (duvelisib) / Secura Bio, Yakult Honsha
P1/2 data, Journal: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. (Pubmed Central) - Sep 17, 2024
P1
These findings support further development of combined PI3K and histone deacetylase (HDAC) inhibition in TCLs and suggest a unique strategy to enable PI3K inhibitor-based combinations for additional patient populations. ClinicalTrials.gov identifier: NCT02783625 .
- | Aliqopa (copanlisib) / Bayer
Journal: Depside and depsidone-rich hydroalcoholic extract, resourced from the lichen Parmelinella wallichiana (Taylor) Elix & Hale selectively restricts non-small cell lung Cancer by modulating p53, FOXO1 and PALLADIN genes. (Pubmed Central) - Sep 15, 2024
inhibitor copanlisib. The study concludes that the extract restricts lung cancer possibly through the PI3K?/FOXO1 axis and thus Parmelinella wallichiana represents a potential resource for anti-lung cancer drug development in future.
- | LY294002 / Eli Lilly
Journal: The role of BTG2/PI3K/AKT pathway-mediated microglial activation in T-2 toxin-induced neurotoxicity. (Pubmed Central) - Sep 15, 2024
Meanwhile, the PI3K inhibitor LY294002 also blocked this process. Therefore, BTG2 may be involved in T-2 toxin's ability to cause microglial activation through PI3K/AKT/NF-?B pathway.
- || Review, Journal: Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential. (Pubmed Central) - Sep 14, 2024
These multidimensional therapeutic combinations present promising strategies for enhancing treatment efficacy and overcoming resistance mechanisms. However, further clinical research is required to validate their effectiveness and safety profiles in hematologic cancer patients.
- | Journal: Design, Synthesis, and Anticancer Activity of Novel Enmein-Type Diterpenoid Derivatives Targeting the PI3K/Akt/mTOR Signaling Pathway. (Pubmed Central) - Sep 14, 2024
This process was associated with elevated intracellular ROS levels and collapsed MMP. In summary, these data identified 7h as a promising lead compound that warrants further investigation of its anticancer properties.
- | Journal: Dehydroevodiamine Alleviates Ulcerative Colitis by Inhibiting the PI3K/AKT/NF-?B Signaling Pathway via Targeting AKT1 and Regulating Gut Microbes and Serum Metabolism. (Pubmed Central) - Sep 14, 2024
Moreover, metabolomics suggested that the regulation of DHE in DSS-induced UC rats mainly involved aminoacyl-tRNA biosynthesis, vitamin B6 metabolism, phenylalanine, tyrosine, and so on. Mechanically, DHE alleviated UC in rats by targeting AKT1, thereby inhibiting the PI3K/AKT/NF-?B signaling pathway.
- ||| Aliqopa (copanlisib) / Bayer, Rituxan (rituximab) / Roche
Clinical, P3 data, Journal: CHRONOS-4: Phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. (Pubmed Central) - Sep 13, 2024
P3
Mechanically, DHE alleviated UC in rats by targeting AKT1, thereby inhibiting the PI3K/AKT/NF-?B signaling pathway. Patients (n
- | Journal: Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer. (Pubmed Central) - Sep 12, 2024
Furthermore, PI3K inhibition could effectively reverse Treg cells upregulation to enhance anti-tumor cytotoxicity of neoantigen-reactive T cells in vitro and reduce tumor growth in the xenograft gastric cancer model. Our study identified the CLDN18-ARHGAP fusion gene as a critical source of immunogenic neoepitopes, a key regulator of the tumor immune microenvironment, and immunotherapeutic applications specific to this oncogenic fusion.
- | Aliqopa (copanlisib) / Bayer
Journal: Molecular modeling strategy for detailing the primary mechanism of action of copanlisib to PI3K: combined ligand-based and target-based approach. (Pubmed Central) - Sep 12, 2024
Finally, MD simulations were performed to elucidate the important interactions between copanlisib and different PI3K subtypes, and highlight the key residues for tight-binding inhibitors. The present study uncovered the principal mechanism of copanlisib's action on PI3K at the theoretical level, and these findings might provide guidance for the rational design of pan-PI3K inhibitors.Communicated by Ramaswamy H. Sarma.
- | Piqray (alpelisib) / Novartis
Journal: A Single Dose of Phosphoinositide-3-kinase Inhibitor Alpelisib Induces Insulin Resistance in Healthy Adults: A Randomized Feasibility Study. (Pubmed Central) - Sep 12, 2024
P1
Single-dose alpelisib was well tolerated and produced metabolic alterations consistent with acute induction of IR, validating its use for mechanistic study of insulin action in humans. (ClinicalTrials.gov registration: NCT05733455).
- | Preclinical, Journal: Traditional Chinese medicine Ze-Qi-Tang formula reduces inflammation in mice with asthma by inhibiting PI3K/AKT/NF-?B signaling pathway. (Pubmed Central) - Sep 12, 2024
Additionally, we discovered that ZQT could suppress the PI3K/AKT/NF-?B pathway in PDGF-BB-induced ASMCs. To sum up, ZQT reduced airway inflammation and remodeling in mice with asthma via inactivating PI3K/AKT/NF-?B pathway.
- | Journal, Metabolomic study: Uncovering the mechanisms of Zhubi decoction against rheumatoid arthritis through an integrated study of network pharmacology, metabolomics, and intestinal flora. (Pubmed Central) - Sep 11, 2024
Furthermore, ZBD modulates host metabolism and intestinal flora. The integrated analysis presents experimental evidence of ZBD for the management of RA.
- | Journal: Uncovering the pharmacological mechanisms of Patchouli essential oil for treating ulcerative colitis. (Pubmed Central) - Sep 11, 2024
The integrated analysis presents experimental evidence of ZBD for the management of RA. This study highlights the mechanisms through which PEO can treat UC, providing a rigorous scientific foundation for future efforts to develop and apply PEO for treating UC.
- | Journal: Newcastle disease virus induces clathrin-mediated endocytosis to establish infection through the activation of PI3K/AKT signaling pathway by VEGFR2. (Pubmed Central) - Sep 10, 2024
This activation primes PI3K, initiating a cascade that promotes clathrin-mediated endocytosis. Our findings elucidate how NDV capitalizes on the PI3K/AKT signaling pathway to establish infection through endocytosis.
- | LY294002 / Eli Lilly
Journal: Asiaticoside protected brain injury in hypertensive intracerebral hemorrhage via activation of the PI3K/AKT pathway. (Pubmed Central) - Sep 10, 2024
Application of LY294002, an inhibitor of PI3K/AKT pathway, reversed the ameliorative effect of AC on the proliferation, apoptosis, angiogenesis and vascular permeability in thrombin-induced hBMECs (p?<?0.05). AC reduced brain damage by increasing the expression of the PI3K/AKT pathway after HICH.
- | Journal: Melatonin mitigates matrix stiffness-induced disc degenetation by inhibiting reactive oxygen species and melatonin receptor mediated-PI3K/AKT/NF-?B pathway. (Pubmed Central) - Sep 9, 2024
The outcomes of the in vivo experiments corroborated the results of the in vitro experiments. Collectively, melatonin can potentially alleviate high matrix stiffness-induced IVDD by reducing intracellular ROS levels and inhibiting the PI3K/AKT/NF-?B pathway.